Ligand Pharmaceuticals Inc (LGND) 101.80 $LGND
Ligand Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 3.20%
Comtex SmarTrend(R) - Tue Nov 10, 4:44PM CST
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $90.66 to a high of $102.76. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $97.77 on volume of 849,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LGND: 101.80 (+2.00)
Stocks Trend Lower; Solar Energy Stocks Socked On Poor Earnings
at Investor's Business Daily - Tue Nov 10, 10:48AM CST
The major indexes were trading lower but in a tight range going into the noon hour Tuesday. The Nasdaq was down 0.6%, the S&P 500 fell 0.2% and the Dow Jones industrial average was off 0.3% in the stock market today. Volume was tracking mixed, with...
DHI: 31.57 (+0.18), FSLR: 53.18 (-1.00), SUNE: 3.37 (-1.19), JAZZ: 142.80 (+5.42), LGND: 101.80 (+2.00), BZH: 13.90 (-0.02), CSIQ: 20.56 (-0.98), JKS: 23.52 (-0.04)
Ligand (LGND) Beats on Q3 Earnings, Lowers 2015 Outlook
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 9:32AM CST
Ligand Pharmaceuticals (LGND) reported third-quarter 2015 earnings of 42 cents per share, significantly higher than the Zacks Consensus Estimate of 21 cents.
SAGE: 45.31 (+2.54), LGND: 101.80 (+2.00), SPPI: 5.20 (+0.05), SNY: 43.78 (+0.66)
Ligand posts 3Q profit
Automated Insights - Mon Nov 09, 4:25PM CST
LA JOLLA, Calif. (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Monday reported third-quarter earnings of $224.5 million.
LGND: 101.80 (+2.00)
Ligand Reports Third Quarter 2015 Financial Results
Business Wire - Mon Nov 09, 3:02PM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2015, and provided an operating forecast and program updates.
LGND: 101.80 (+2.00)
What Awaits Ligand Pharmaceuticals (LGND) in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 3:25PM CST
Ligand Pharmaceuticals LGND), which is scheduled to report third-quarter results on Nov 9, had recorded a positive earnings surprise of 7.95% last quarter.
MACK: 8.50 (-0.08), LGND: 101.80 (+2.00), AMGN: 158.74 (+4.24), SNY: 43.78 (+0.66)
Here's Why Spectrum Pharmaceuticals' Stock Plunged Today
George Budwell, The Motley Fool - Motley Fool - Fri Oct 23, 12:01PM CDT
What : Spectrum Pharmaceuticals , a biotech company that develops and commercializes oncology and hematology drug products, saw its shares crater by as much as 26% today on exceptionally high volume. This drop was triggered by the announcement that...
LGND: 101.80 (+2.00), SPPI: 5.20 (+0.05)
Spectrum Pharmaceuticals' Evomela Gets CRL in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:12AM CDT
Spectrum (SPPI) announced that it has received a Complete Response Letter (CRL) from the FDA for Evomela.
AZN: 33.38 (+0.60), LGND: 101.80 (+2.00), AMGN: 158.74 (+4.24), SPPI: 5.20 (+0.05)
Ligand to Report Third Quarter Results on November 9th
Business Wire - Tue Oct 20, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2015 financial results on November 9, 2015. Ligand's CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call.
LGND: 101.80 (+2.00)
Ligand to Host Analyst Day on November 18th in New York City
Business Wire - Mon Oct 12, 3:01PM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Wednesday, November 18, 2015 from 10:00 a.m. to 11:30 a.m. Eastern time (7:00 a.m. to 8:30 a.m. Pacific time) in New York City.
LGND: 101.80 (+2.00)
Ligand, SAGE Captisol Partnership to Also Include SAGE-689
Zacks Equity Research - Zacks Investment Research - Wed Sep 30, 3:55PM CDT
Ligand Pharmaceuticals (LGND) expanded its existing partnership with SAGE Therapeutics for the development and commercialization of Captisol-enabled SAGE-689.
SAGE: 45.31 (+2.54), LGND: 101.80 (+2.00), AMGN: 158.74 (+4.24), NVS: 87.79 (+0.74)
Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689
Business Wire - Tue Sep 29, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has expanded its global license and supply agreements with SAGE Therapeutics (SAGE) to now also cover the use of Captisol(R) in the development and commercialization of SAGE-689. Under the terms of the license, Ligand received a licensing fee and will be eligible to receive potential milestone payments, tiered royalties on future net sales and revenue from Captisol material sales. SAGE will be responsible for all costs related to the program.
SAGE: 45.31 (+2.54), LGND: 101.80 (+2.00)
The Fastest-Growing Biotech Stocks
Sean Williams, The Motley Fool - Motley Fool - Mon Sep 21, 5:07PM CDT
Source: Flickr user Maryland GovPics. Even after the first correction in four years, biotech stocks are absolutely crushing the S&P 500 over the trailing-five-year period. In fact, the SPDR S&P Biotech ETF has more than quadrupled the...
SUPN: 16.76 (+0.65), LGND: 101.80 (+2.00), PCRX: 56.38 (+0.66)
FDA Expands Use of Promacta(R) to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia
Business Wire - Mon Aug 24, 12:00PM CDT
--For about one in four children with ITP, the condition persists for more than 12 months after diagnosis and is considered chronic(1,2)
LGND: 101.80 (+2.00)
Collegium's Xtampza to be Reviewed by FDA Advisory Panels
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 2:20PM CDT
Collegium (COLL) announced that the FDA's advisory committees will meet to review the New Drug Application for Xtampza ER.
COLL: 17.93 (-0.52), LGND: 101.80 (+2.00), AMAG: 29.53 (+1.24), HSP: 89.95 (-0.01)
Endo Beats on Q2 Earnings and Revenues, Maintains View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 10:40AM CDT
Endo International (ENDP) reported second quarter 2015 earnings of $1.08 per share.
BSX: 17.65 (-0.09), ENDP: 58.50 (+1.60), VRX: 71.63 (-1.69), LGND: 101.80 (+2.00)
Watch for Ligand Pharmaceuticals to Potentially Rebound After Falling 10.00% Yesterday
Comtex SmarTrend(R) - Fri Aug 07, 4:44PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $91.69 to a high of $104.50. Yesterday, the shares fell 10.0%, which took the trading range below the 3-day low of $102.47 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LGND: 101.80 (+2.00)
Synta's Q2 Loss Narrower than Expected, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 07, 8:50AM CDT
Synta Pharmaceuticals Corp. (SNTA) reported a second-quarter 2015 loss of 15 cents per share.
SNTA: 0.41 (-0.02), VRX: 71.63 (-1.69), LGND: 101.80 (+2.00), ANAC: 112.68 (+3.22)
These Two Biotechs Boast Big EPS Growth Rates
at Investor's Business Daily - Thu Aug 06, 3:13PM CDT
IBD's Medical-Biomed/Biotech group holds the No. 1 spot on the list of 197 industry groups tracked, as several of its members topped Street forecasts over the past week. Today's Screen of the Day focuses on Top Fundamentals, stocks with three-year...
LCI: 36.25 (+0.88), BIIB: 281.96 (-1.57), INSY: 29.83 (+1.19), GILD: 104.58 (+0.77), SCMP: 17.12 (-0.18), LGND: 101.80 (+2.00), AMGN: 158.72 (+4.22), REGN: 570.83 (+12.45), CELG: 111.49 (+1.35)
Jazz Pharmaceuticals Misses on Q2 Earnings, Affirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 2:12PM CDT
Jazz Pharmaceuticals (JAZZ) reported second-quarter 2015 earnings of $2.11 per share, substantially lower than the Zacks Consensus Estimate of $2.16.
GILD: 104.58 (+0.77), JAZZ: 142.80 (+5.42), LGND: 101.80 (+2.00)
Ligand Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 3.20%
Comtex SmarTrend(R) - Tue Nov 10, 4:44PM CST
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $90.66 to a high of $102.76. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $97.77 on volume of 849,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LGND: 101.80 (+2.00)
Stocks Trend Lower; Solar Energy Stocks Socked On Poor Earnings
at Investor's Business Daily - Tue Nov 10, 10:48AM CST
The major indexes were trading lower but in a tight range going into the noon hour Tuesday. The Nasdaq was down 0.6%, the S&P 500 fell 0.2% and the Dow Jones industrial average was off 0.3% in the stock market today. Volume was tracking mixed, with...
DHI: 31.57 (+0.18), FSLR: 53.18 (-1.00), SUNE: 3.37 (-1.19), JAZZ: 142.80 (+5.42), LGND: 101.80 (+2.00), BZH: 13.90 (-0.02), CSIQ: 20.56 (-0.98), JKS: 23.52 (-0.04)
Ligand (LGND) Beats on Q3 Earnings, Lowers 2015 Outlook
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 9:32AM CST
Ligand Pharmaceuticals (LGND) reported third-quarter 2015 earnings of 42 cents per share, significantly higher than the Zacks Consensus Estimate of 21 cents.
SAGE: 45.31 (+2.54), LGND: 101.80 (+2.00), SPPI: 5.20 (+0.05), SNY: 43.78 (+0.66)
Ligand posts 3Q profit
Automated Insights - Mon Nov 09, 4:25PM CST
LA JOLLA, Calif. (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Monday reported third-quarter earnings of $224.5 million.
LGND: 101.80 (+2.00)
Ligand Reports Third Quarter 2015 Financial Results
Business Wire - Mon Nov 09, 3:02PM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2015, and provided an operating forecast and program updates.
LGND: 101.80 (+2.00)
What Awaits Ligand Pharmaceuticals (LGND) in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 3:25PM CST
Ligand Pharmaceuticals LGND), which is scheduled to report third-quarter results on Nov 9, had recorded a positive earnings surprise of 7.95% last quarter.
MACK: 8.50 (-0.08), LGND: 101.80 (+2.00), AMGN: 158.74 (+4.24), SNY: 43.78 (+0.66)
Here's Why Spectrum Pharmaceuticals' Stock Plunged Today
George Budwell, The Motley Fool - Motley Fool - Fri Oct 23, 12:01PM CDT
What : Spectrum Pharmaceuticals , a biotech company that develops and commercializes oncology and hematology drug products, saw its shares crater by as much as 26% today on exceptionally high volume. This drop was triggered by the announcement that...
LGND: 101.80 (+2.00), SPPI: 5.20 (+0.05)
Spectrum Pharmaceuticals' Evomela Gets CRL in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:12AM CDT
Spectrum (SPPI) announced that it has received a Complete Response Letter (CRL) from the FDA for Evomela.
AZN: 33.38 (+0.60), LGND: 101.80 (+2.00), AMGN: 158.74 (+4.24), SPPI: 5.20 (+0.05)
Ligand to Report Third Quarter Results on November 9th
Business Wire - Tue Oct 20, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2015 financial results on November 9, 2015. Ligand's CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call.
LGND: 101.80 (+2.00)
Ligand to Host Analyst Day on November 18th in New York City
Business Wire - Mon Oct 12, 3:01PM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Wednesday, November 18, 2015 from 10:00 a.m. to 11:30 a.m. Eastern time (7:00 a.m. to 8:30 a.m. Pacific time) in New York City.
LGND: 101.80 (+2.00)
Ligand, SAGE Captisol Partnership to Also Include SAGE-689
Zacks Equity Research - Zacks Investment Research - Wed Sep 30, 3:55PM CDT
Ligand Pharmaceuticals (LGND) expanded its existing partnership with SAGE Therapeutics for the development and commercialization of Captisol-enabled SAGE-689.
SAGE: 45.31 (+2.54), LGND: 101.80 (+2.00), AMGN: 158.74 (+4.24), NVS: 87.79 (+0.74)
Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689
Business Wire - Tue Sep 29, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has expanded its global license and supply agreements with SAGE Therapeutics (SAGE) to now also cover the use of Captisol(R) in the development and commercialization of SAGE-689. Under the terms of the license, Ligand received a licensing fee and will be eligible to receive potential milestone payments, tiered royalties on future net sales and revenue from Captisol material sales. SAGE will be responsible for all costs related to the program.
SAGE: 45.31 (+2.54), LGND: 101.80 (+2.00)
The Fastest-Growing Biotech Stocks
Sean Williams, The Motley Fool - Motley Fool - Mon Sep 21, 5:07PM CDT
Source: Flickr user Maryland GovPics. Even after the first correction in four years, biotech stocks are absolutely crushing the S&P 500 over the trailing-five-year period. In fact, the SPDR S&P Biotech ETF has more than quadrupled the...
SUPN: 16.76 (+0.65), LGND: 101.80 (+2.00), PCRX: 56.38 (+0.66)
FDA Expands Use of Promacta(R) to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia
Business Wire - Mon Aug 24, 12:00PM CDT
--For about one in four children with ITP, the condition persists for more than 12 months after diagnosis and is considered chronic(1,2)
LGND: 101.80 (+2.00)
Collegium's Xtampza to be Reviewed by FDA Advisory Panels
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 2:20PM CDT
Collegium (COLL) announced that the FDA's advisory committees will meet to review the New Drug Application for Xtampza ER.
COLL: 17.93 (-0.52), LGND: 101.80 (+2.00), AMAG: 29.53 (+1.24), HSP: 89.95 (-0.01)
Endo Beats on Q2 Earnings and Revenues, Maintains View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 10:40AM CDT
Endo International (ENDP) reported second quarter 2015 earnings of $1.08 per share.
BSX: 17.65 (-0.09), ENDP: 58.50 (+1.60), VRX: 71.63 (-1.69), LGND: 101.80 (+2.00)
Watch for Ligand Pharmaceuticals to Potentially Rebound After Falling 10.00% Yesterday
Comtex SmarTrend(R) - Fri Aug 07, 4:44PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $91.69 to a high of $104.50. Yesterday, the shares fell 10.0%, which took the trading range below the 3-day low of $102.47 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LGND: 101.80 (+2.00)
Synta's Q2 Loss Narrower than Expected, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 07, 8:50AM CDT
Synta Pharmaceuticals Corp. (SNTA) reported a second-quarter 2015 loss of 15 cents per share.
SNTA: 0.41 (-0.02), VRX: 71.63 (-1.69), LGND: 101.80 (+2.00), ANAC: 112.68 (+3.22)
These Two Biotechs Boast Big EPS Growth Rates
at Investor's Business Daily - Thu Aug 06, 3:13PM CDT
IBD's Medical-Biomed/Biotech group holds the No. 1 spot on the list of 197 industry groups tracked, as several of its members topped Street forecasts over the past week. Today's Screen of the Day focuses on Top Fundamentals, stocks with three-year...
LCI: 36.25 (+0.88), BIIB: 281.96 (-1.57), INSY: 29.83 (+1.19), GILD: 104.58 (+0.77), SCMP: 17.12 (-0.18), LGND: 101.80 (+2.00), AMGN: 158.72 (+4.22), REGN: 570.83 (+12.45), CELG: 111.49 (+1.35)
Jazz Pharmaceuticals Misses on Q2 Earnings, Affirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 2:12PM CDT
Jazz Pharmaceuticals (JAZZ) reported second-quarter 2015 earnings of $2.11 per share, substantially lower than the Zacks Consensus Estimate of $2.16.
GILD: 104.58 (+0.77), JAZZ: 142.80 (+5.42), LGND: 101.80 (+2.00)
